Compounded Semaglutide Safety profilety Guide: How to Verify Your Provider

503A vs 503B Compounding Pharmacies - The Critical Distinction

The single most important thing you can understand about compounded semaglutide safety is the difference between two types of compounding pharmacies defined by the Federal Food, Drug, and Cosmetic Act. These two designations - 503A and 503B - represent fundamentally different levels of regulation, testing, and accountability. Understanding this distinction is the foundation of everything else in this guide.

What Is a 503A Compounding Pharmacy?

Section 503A of the Federal Food, Drug, and Cosmetic Act defines the traditional model of pharmacy compounding. A 503A compounding pharmacy is the neighborhood compounding pharmacy that has existed for over a century - a licensed pharmacist who prepares customized medications for individual patients based on specific prescriptions from licensed practitioners.

Under Section 503A, a compounding pharmacy must operate under a valid prescription for an individually identified patient. The pharmacist compounds the medication based on the specific clinical needs of that patient, such as adjusting the dose, changing the delivery form, or removing an allergen. This is the model that allows a pharmacist to prepare a liquid version of a medication for a child who cannot swallow pills, or to compound a cream at a specific concentration that is not commercially available.

The key regulatory characteristics of 503A pharmacies include the following. They are primarily regulated by state boards of pharmacy rather than the FDA. They are not required to register with the FDA as drug manufacturers or outsourcing facilities. They are not required to follow the FDA current Good Manufacturing Practice (cGMP) regulations that apply to drug manufacturers. They are not required to report adverse events to the FDA. They compound medications for individual patients based on prescriptions and generally cannot compound large batches in advance without patient-specific orders.

This does not mean that 503A pharmacies are unregulated. They must hold valid state pharmacy licenses, employ licensed pharmacists, follow state pharmacy practice laws, and comply with United States Pharmacopeia (USP) standards for compounding including USP 795 for non-sterile compounding and USP 797 for sterile compounding. Many 503A pharmacies produce excellent, safe compounded medications. However, the level of oversight is fundamentally different from what applies to 503B facilities.

The challenge with 503A compounding for injectable medications like semaglutide is the limited federal oversight. While state boards of pharmacy conduct inspections, the frequency and rigor of these inspections vary dramatically from state to state. Some states inspect compounding pharmacies annually with thorough reviews of sterile compounding practices. Others may inspect less frequently or with less focus on the technical requirements of sterile compounding.

What Is a 503B Outsourcing Facility?

Section 503B of the Federal Food, Drug, and Cosmetic Act was created by the Drug Quality and Security Act (DQSA) of 2013, which was passed by Congress in direct response to the 2012 New England Compounding Center (NECC) tragedy. In that incident, contaminated compounded steroid injections from NECC caused a nationwide fungal meningitis outbreak that killed 76 people and sickened over 750 others. The DQSA was designed to create a higher tier of compounding oversight that would prevent such catastrophic failures.

A 503B outsourcing facility is a compounding operation that has voluntarily elected to register with the FDA and submit to a significantly higher level of federal oversight. By registering as a 503B facility, a compounder agrees to operate under conditions that are much closer to those of a traditional pharmaceutical manufacturer than a traditional compounding pharmacy.

The key regulatory characteristics of 503B outsourcing facilities include the following. They must register with the FDA and are listed on the FDA public database of registered outsourcing facilities. They must comply with current Good Manufacturing Practice (cGMP) requirements under 21 CFR Parts 210 and 211. They are subject to FDA inspection on a risk-based schedule, typically every one to two years. They must report serious adverse events to the FDA within 15 days. They must include on each product label the facility name and address, active and inactive ingredients, lot number, and beyond-use dating. They can compound medications in larger batches without patient-specific prescriptions, distributing them to healthcare practitioners and facilities. They must test every batch for potency, sterility, and other quality attributes before release.

The cGMP requirements are the cornerstone of 503B safety. These are the same manufacturing standards that apply to companies like Pfizer, Merck, and Novo Nordisk when they produce FDA-approved pharmaceuticals. While 503B facilities compound rather than manufacture FDA-approved drugs, they must meet the same process controls, environmental standards, documentation practices, and quality testing requirements as large-scale pharmaceutical manufacturers.

Why This Distinction Matters for Semaglutide

For oral medications like tablets and capsules, the difference between 503A and 503B compounding may be less clinically significant. But for injectable medications like semaglutide, this distinction becomes critically important. Injectable drugs bypass the body's natural defense barriers - the skin, the digestive system, the liver - and enter the bloodstream directly. Any contaminant in an injectable product has direct access to the body's most vulnerable systems.

A semaglutide injection that contains bacterial endotoxins can trigger a severe inflammatory response. One that contains bacterial or fungal contamination can cause a localized abscess, a systemic bloodstream infection, or worse. An injection with incorrect potency can either provide no therapeutic benefit or deliver a dangerously high dose. These are not theoretical risks - they are documented outcomes of poorly compounded injectable medications.

This is why the 503B outsourcing facility model exists. When you receive compounded semaglutide from a 503B facility, you know that the environment where it was prepared meets federal cleanroom standards, that every batch was tested for sterility before release, that the potency was verified to be within acceptable limits, that endotoxin testing was performed, and that the FDA has inspected the facility and found it compliant with cGMP requirements.

The Hybrid Reality: How 503A Pharmacies Often Operate in the GLP-1 Space

One of the more complex aspects of the current compounded semaglutide market is that many telehealth platforms and online providers partner with 503A compounding pharmacies rather than 503B outsourcing facilities. This creates a situation where patients may believe they are receiving the same level of quality assurance provided by a federally regulated facility when they are actually receiving products from a state-regulated pharmacy with less rigorous oversight requirements.

Some 503A pharmacies that compound semaglutide voluntarily implement quality practices that exceed their legal requirements. They may perform sterility testing on every batch, conduct potency assays, maintain cleanroom environments that meet or exceed USP 797 standards, and provide Certificates of Analysis. These pharmacies deserve credit for going above and beyond. However, these practices are voluntary, not mandated, and there is no federal enforcement mechanism ensuring they continue.

The fundamental question for consumers is this: would you rather receive an injectable medication from a facility where batch testing, cleanroom standards, and adverse event reporting are mandatory and federally enforced, or from a facility where those same practices are optional and self-reported? For most patients, particularly those new to compounded medications, the 503B model provides a significantly higher margin of safety.

FDA Compounding Regulations in 2026: What Has Changed and What It Means for You

The regulatory space for compounded semaglutide has been one of the most dynamic areas of FDA policy in recent years. Understanding the current state of FDA compounding regulations is essential for anyone using or considering compounded GLP-1 medications, because these regulations directly determine which products are legal, which pharmacies can produce them, and what quality standards apply.

The Drug Quality and Security Act (DQSA) of 2013 - Foundation of Current Law

The cornerstone of current compounding regulation is the Drug Quality and Security Act, signed into law on November 27, 2013. This legislation was Congress's response to the NECC fungal meningitis outbreak and represented the most significant overhaul of pharmacy compounding regulation in decades. The DQSA amended the Federal Food, Drug, and Cosmetic Act to create the two-tier system of 503A and 503B compounding that governs the market today.

Under the DQSA, the FDA gained explicit authority over 503B outsourcing facilities while largely preserving the traditional state-regulatory model for 503A pharmacies. The law established that 503B facilities must register with the FDA, comply with cGMP, submit to FDA inspections, report adverse events, and label products with specific information. It also established conditions under which compounders can prepare copies of commercially available drugs, including during declared drug shortages.

The Drug Shortage Exception and Semaglutide

One of the most consequential provisions of the DQSA for the compounded semaglutide market is the drug shortage exception. Under both Section 503A and Section 503B, compounders may compound copies of commercially available drugs when those drugs appear on the FDA Drug Shortage List. Semaglutide injection products (Ozempic and Wegovy) were placed on the FDA Drug Shortage List due to unprecedented demand that outstripped Novo Nordisk's manufacturing capacity.

While semaglutide appeared on the shortage list, compounding pharmacies had clear legal authority to compound semaglutide products. This enabled the rapid growth of the compounded semaglutide market, with hundreds of pharmacies and dozens of telehealth platforms offering compounded alternatives to brand-name products. The legal space became more complex when Novo Nordisk increased production capacity and certain semaglutide presentations began to come off the shortage list.

The FDA has taken the position that when a drug is no longer on the shortage list, the drug shortage exception no longer applies, and compounders must cease production of copies of that commercially available drug. However, the legal and practical implementation of this position has been subject to litigation, with several compounding pharmacies and industry organizations challenging the FDA's interpretation in federal court.

The Evolving Regulatory space in 2025-2026

Throughout 2025 and into 2026, the FDA has continued to refine and enforce its compounding policies related to semaglutide. Several key developments have shaped the current space.

The FDA has increased its inspection frequency of 503B outsourcing facilities producing semaglutide products, reflecting the high volume and high public interest in these products. Inspection findings have been publicly released, giving consumers and healthcare providers visibility into the compliance status of specific facilities.

The agency has also issued multiple guidance documents clarifying its expectations for compounders, including guidance on the drug shortage exception, the use of bulk drug substances in compounding, and the distinction between compounding and manufacturing. While FDA guidance documents are not legally binding, they represent the agency's current thinking and enforcement priorities.

Congressional interest in compounding regulation has also intensified, with multiple hearings examining the balance between patient access to compounded medications and safety oversight. Proposed legislation has sought to both expand patient access to compounded GLP-1 medications and strengthen quality requirements for compounders operating in this space.

State-Level Regulation: The Patchwork Problem

While federal regulation of 503B facilities is relatively uniform, state regulation of 503A pharmacies varies dramatically across the country. This creates a patchwork of standards that can be confusing for consumers, particularly those who use telehealth services that may be connected to compounding pharmacies in different states.

Some states have adopted stringent compounding regulations that closely mirror federal cGMP requirements. These states may require sterility testing for every batch of compounded sterile preparations, mandate cleanroom environmental monitoring, require pharmacist competency assessments specific to sterile compounding, and conduct rigorous annual inspections of compounding operations.

Other states have less specific or less rigorously enforced compounding regulations. In these jurisdictions, a 503A pharmacy may be legally compliant while operating under standards that would not meet the expectations of more stringent states or federal 503B requirements. This variability is one of the primary reasons that many patient safety advocates and healthcare organizations recommend 503B outsourcing facilities for high-risk compounded preparations like injectable semaglutide.

Recent FDA Warning Letters and Enforcement Actions

The FDA's enforcement activity related to compounded semaglutide products has been among the most active areas of the agency's compounding oversight program. Warning letters, import alerts, and other enforcement actions provide a window into the types of safety violations the FDA is finding - and what consumers should be aware of when evaluating potential providers.

Understanding FDA Warning Letters

An FDA warning letter is a formal communication from the agency to a company or individual that the FDA considers to be in significant violation of federal law or regulations. Warning letters are not final agency actions - they are typically a precursor to more formal enforcement and give the recipient an opportunity to correct the violations. However, they represent a serious finding by the FDA and are made publicly available on the FDA website.

For consumers, FDA warning letters serve as a critical transparency tool. You can search the FDA warning letter database for any compounding pharmacy or outsourcing facility to see if the agency has identified compliance problems. A warning letter does not necessarily mean a product is unsafe - some violations are procedural or documentation-related - but it does indicate that the FDA found significant issues during its review.

Common Violations Identified in Semaglutide-Related Enforcement

Based on publicly available FDA enforcement actions related to compounded semaglutide and similar peptide products, the following categories of violations have been most frequently cited.

Production of compounded products using salt forms. The FDA has cited multiple facilities for compounding semaglutide using salt forms (such as semaglutide sodium or semaglutide acetate) that the FDA considers to be different active ingredients from the base form of semaglutide used in FDA-approved products. This is a central issue in the ongoing salt form controversy discussed later in this guide.

Insanitary conditions. Some facilities have been cited for environmental control failures including inadequate cleanroom conditions, failures in air handling systems, inadequate cleaning and sanitization procedures, and deficiencies in personnel gowning and aseptic technique. These findings are among the most serious because they directly impact the sterility of injectable products.

Failure to perform adequate testing. The FDA has cited facilities that failed to perform required sterility testing, potency assays, endotoxin testing, or other quality control measures on compounded semaglutide products. In some cases, facilities released products before completing required testing or relied on incomplete or invalid test results.

Labeling violations. Products that lack required labeling information - including lot numbers, beyond-use dates, complete ingredient lists, and facility identification - have been subject to enforcement action. Proper labeling is essential for traceability and for patients and healthcare providers to make informed decisions.

Distribution without proper registration. Some entities that the FDA considers to be operating as outsourcing facilities or drug manufacturers have been cited for distributing compounded semaglutide without proper FDA registration. This includes entities that compound and distribute products across state lines in quantities that exceed what the FDA considers traditional 503A compounding.

Marketing violations. The FDA has taken action against entities that market compounded semaglutide products with claims that they are equivalent to, identical to, or interchangeable with FDA-approved products like Ozempic or Wegovy. Such claims constitute misbranding under federal law because compounded products have not undergone the same clinical trials and FDA review process as approved drugs.

How to Check for FDA Warning Letters

Before choosing a compounded semaglutide provider, you should check whether the pharmacy or outsourcing facility has received any FDA warning letters. Follow these steps:

1. Visit the FDA Warning Letters page at fda.gov and search by company name
2. Check the FDA Inspections database for the facility's inspection history and findings
3. Search the FDA Registered Outsourcing Facilities list to confirm 503B registration status
4. Review your state board of pharmacy's disciplinary action records
5. Ask the provider directly whether they have received any FDA warning letters or state board actions, and request documentation of their response and remediation

A facility that has received a warning letter and successfully addressed all cited violations may actually demonstrate a commitment to compliance - the response to a warning letter can be as informative as the letter itself. However, a facility with multiple unresolved warning letters, or one that has received a warning letter and shows no evidence of remediation, should be avoided.

Quality Testing Requirements for Compounded Semaglutide

Quality testing is the technical backbone of compounded medication safety. For injectable semaglutide, comprehensive testing ensures that each vial contains the correct amount of active ingredient, is free from microbial contamination and endotoxins, meets physical specifications for injectability, and will remain stable through its labeled beyond-use date. Understanding what testing should be performed - and what the results mean - helps you to evaluate any compounding pharmacy's quality claims with confidence.

USP 797: The Gold Standard for Sterile Compounding

United States Pharmacopeia Chapter 797 (USP 797) establishes the standards for compounding sterile preparations in the United States. Revised and updated in 2023, USP 797 defines requirements across multiple domains that directly impact the safety of compounded injectable products like semaglutide.

Cleanroom environment. USP 797 specifies ISO-classified cleanroom environments for sterile compounding. The primary engineering control - typically a laminar airflow workbench or biological safety cabinet - must provide ISO Class 5 air quality at the point of compounding. This means fewer than 3,520 particles of 0.5 micrometers or larger per cubic meter of air. The surrounding buffer area must meet ISO Class 7 standards, and the ante area must meet ISO Class 8 standards. These classifications are verified through regular air sampling and particulate monitoring.

Personnel training and competency. All personnel involved in sterile compounding must complete didactic training, pass written assessments, and demonstrate competency in aseptic technique through media fill testing. Media fill tests involve the compounder performing the entire compounding process using microbiological growth media instead of the actual drug. The media is then incubated to check for microbial growth, which would indicate a break in aseptic technique. Personnel must pass media fill testing initially and at regular intervals thereafter.

Environmental monitoring. Ongoing environmental monitoring is required to verify that the cleanroom continues to meet required air quality standards during actual compounding operations. This includes viable air sampling (testing for living microorganisms), non-viable particle counting, surface sampling of critical surfaces, and personnel sampling (glove fingertip and thumb testing). Monitoring must be performed at defined intervals and results must be documented and reviewed.

Beyond-use dating (BUD). USP 797 establishes default beyond-use dates for compounded sterile preparations based on the risk level of the compounding process and storage conditions. Facilities can extend BUDs beyond the defaults through stability testing that demonstrates the preparation maintains its quality attributes through the extended date. For compounded semaglutide, appropriate BUD assignment is critical because the peptide can degrade over time, particularly at improper temperatures.

Sterility Testing

Sterility testing confirms that a compounded injectable product is free from viable microorganisms. This is arguably the single most important quality test for any injectable product. For compounded semaglutide, sterility testing typically follows USP Chapter 71 methodology.

The test involves taking samples from a batch of compounded product and exposing them to microbiological growth media under conditions favorable for microbial growth. The media are incubated for a minimum of 14 days - 7 days at 20 to 25 degrees Celsius to detect mold and yeast, and 7 days at 30 to 35 degrees Celsius to detect bacteria. If no microbial growth is observed after the full incubation period, the batch passes sterility testing.

For 503B outsourcing facilities operating under cGMP, sterility testing of every batch is mandatory before the product can be released for distribution. This is a fundamental requirement that cannot be waived or deferred. If a batch fails sterility testing, it must be rejected and destroyed - it cannot be retested and released.

The implications of sterility testing failure are severe. A non-sterile injectable product introduced into a patient can cause local infections at the injection site, systemic bloodstream infections (sepsis), abscess formation, and in the most severe cases, life-threatening systemic fungal or bacterial infections. The NECC tragedy that killed 76 people was caused precisely by this type of contamination in injectable products.

Potency Assay

Potency testing verifies that the compounded product contains the correct amount of active ingredient. For semaglutide, this means confirming that each vial contains the amount of semaglutide stated on the label, within acceptable limits. The standard acceptable range for potency is typically 90 to 110 percent of the labeled amount, though some facilities maintain tighter specifications.

Potency testing for semaglutide is typically performed using high-performance liquid chromatography (HPLC), which separates and quantifies the active pharmaceutical ingredient in the formulation. This is the same analytical technique used by Novo Nordisk and other pharmaceutical manufacturers to verify the potency of their FDA-approved products.

Why does potency matter so much for semaglutide? Because semaglutide is dosed in relatively small quantities (micrograms to milligrams), and the dose-response relationship is clinically significant. A product with potency below specification may fail to produce the expected therapeutic effect, leading patients to believe the medication is not working. A product with potency above specification could cause more severe gastrointestinal side effects or other adverse reactions associated with higher doses. Either scenario represents a patient safety concern.

Bacterial Endotoxin (LAL) Testing

Bacterial endotoxin testing, commonly performed using the Limulus Amebocyte Lysate (LAL) assay per USP Chapter 85, detects the presence of endotoxins in injectable products. Endotoxins are components of the cell walls of gram-negative bacteria that can trigger severe inflammatory responses in humans even in the absence of viable bacteria.

This distinction is critical: a product can pass sterility testing (no living bacteria present) but still contain dangerous levels of endotoxins from bacteria that were present during the compounding process and subsequently killed or removed. Endotoxins are extremely heat-stable and are not destroyed by standard sterilization processes. Injection of endotoxin-contaminated products can cause fever (pyrogenic reaction), chills, hypotension, and in severe cases, septic shock.

The LAL test uses a reagent derived from the blood cells of the horseshoe crab (Limulus polyphemus) that clots in the presence of endotoxins. The test can detect endotoxin concentrations as low as 0.005 endotoxin units per milliliter, making it an extremely sensitive quality control measure. For injectable pharmaceutical products, endotoxin limits are established in USP and must not be exceeded.

Additional Quality Tests

Beyond the three cornerstone tests of sterility, potency, and endotoxin, several additional quality tests should be performed on compounded semaglutide products.

pH testing. The pH of an injectable product must fall within a range that is both compatible with the stability of the active ingredient and suitable for injection. Semaglutide formulations typically have a pH in the range of approximately 7.0 to 8.0. A pH outside the specified range can indicate formulation problems, degradation of the active ingredient, or potential for injection site irritation.

Particulate matter testing (USP 788). Injectable products must be essentially free from visible particulate matter and must meet established limits for sub-visible particles. Particulate contamination can cause injection site reactions, vascular occlusion, and granuloma formation. Testing is performed using light obscuration or microscopic particle counting methods.

Container closure integrity testing. The seal between the vial stopper and the vial must maintain its integrity throughout the product's beyond-use date to prevent microbial ingress and maintain sterility. This is particularly important for multi-dose vials that are accessed multiple times with a needle.

Identity testing. Analytical testing must confirm the identity of the active ingredient in the finished product. This ensures that the correct drug substance was used in compounding and that no mix-ups occurred during the preparation process.

Appearance testing. Each batch should be visually inspected for clarity, color, and absence of visible particulate matter. Semaglutide injection should be a clear, colorless to slightly yellow solution. Cloudiness, discoloration, or visible particles indicate a quality problem and the product should not be used.

USP 800: Handling Hazardous Drugs

While semaglutide itself is not classified as a hazardous drug under USP 800, compounding facilities that produce a range of products must maintain compliance with USP 800 for applicable compounds. Understanding that a facility follows USP 800 where required indicates a broader commitment to pharmaceutical safety standards and personnel protection that reflects positively on the facility's overall quality culture.

The Testing Gap: What Happens When Tests Are Skipped

When a compounding pharmacy skips or shortcutes quality testing, the consequences are not immediately visible. A vial of semaglutide that was compounded in a contaminated environment looks identical to one prepared in a validated cleanroom. A product with 60 percent of the labeled potency looks the same as one with 100 percent. A product contaminated with endotoxins is indistinguishable by visual inspection from a clean product.

This is precisely why testing is so important and why the distinction between mandatory testing (503B) and voluntary testing (503A) matters. Without testing, there is no way to know whether a compounded injectable product is safe. You cannot see bacteria. You cannot see endotoxins. You cannot see a 40 percent potency shortfall. Only analytical testing can provide this assurance, and only facilities that are required to perform it on every batch can be relied upon to do so consistently.

How to Read a Certificate of Analysis (CoA)

A Certificate of Analysis is the single most important document a consumer can review when evaluating a compounded semaglutide product. The CoA is a formal document that summarizes the results of quality testing performed on a specific batch of medication. Learning to read and interpret a CoA gives you the ability to independently verify the quality claims of any compounding pharmacy - and to identify red flags that might indicate substandard products.

What Should Be on a CoA

A complete Certificate of Analysis for compounded semaglutide should contain all of the following elements. Missing elements should raise questions, and a provider that cannot produce a CoA at all should be avoided entirely.

Product identification. The CoA should clearly identify the product, including the drug name (semaglutide), concentration (e.g., 5 mg/mL), volume, and dosage form (injection, solution for subcutaneous injection). This information should match exactly what appears on the product label.

Lot or batch number. Every batch of compounded medication should be assigned a unique lot number that allows traceability. The lot number on the CoA should match the lot number on the vial you receive. If they do not match, you cannot be certain that the test results apply to your specific product.

Manufacturing and testing dates. The CoA should indicate when the batch was compounded and when testing was performed. Testing should be completed before the product is released for distribution. If testing dates are after the distribution date, that means the product was released before testing was complete - a serious compliance violation.

Beyond-use date (BUD). The assigned beyond-use date should appear on the CoA and should be supported by stability data. The BUD on the CoA should match the BUD on the product label.

Test results for each quality parameter. For each test performed, the CoA should list the test name, the method used, the specification or acceptance criteria, and the actual result. Results should clearly indicate whether the batch passed or failed each test.

Laboratory identification. The CoA should identify the laboratory that performed the testing, whether in-house or third-party. Third-party laboratory testing provides an additional layer of independence and credibility.

Authorized signatures. The CoA should be signed or electronically authorized by the responsible quality assurance personnel, indicating that the results have been reviewed and approved for batch release.

How to Interpret CoA Results

When reviewing a CoA for compounded semaglutide, focus on the following key results.

Potency (Assay). Look for a result between 90 and 110 percent of the labeled claim. A result of 95 to 105 percent indicates excellent compounding precision. Results outside the 90 to 110 percent range mean the product does not meet standard pharmaceutical specifications. For example, if a vial is labeled as 5 mg/mL semaglutide, the assay result should show between 4.5 and 5.5 mg/mL.

Sterility. The result should state "No growth observed" or "Pass" after the full 14-day incubation period. Any indication of microbial growth means the batch failed and should have been rejected. If the CoA shows sterility testing is "in progress" or "pending," the product was released before sterility was confirmed - this is a significant red flag.

Endotoxin (LAL). The result should show a value below the specified limit, typically expressed in endotoxin units per milliliter (EU/mL) or endotoxin units per milligram of active ingredient. The result should be well below the limit, not right at the boundary.

pH. The pH value should fall within the specified range. A pH significantly outside the expected range can indicate degradation or formulation errors.

Particulate matter. Results should show particle counts below USP 788 limits. This test confirms the product is sufficiently clean for injection.

Requesting and Verifying a CoA

Every consumer has the right to request a Certificate of Analysis for their specific lot of compounded semaglutide. Here is how to do it effectively.

Contact your provider or the compounding pharmacy directly and request the CoA for the specific lot number printed on your vial. A reputable provider should be able to furnish this document within a reasonable timeframe - usually 24 to 48 hours. Some providers make CoAs available through their patient portal or include them with shipments.

When you receive the CoA, verify that the lot number matches your product, that all required tests were performed and passed, that testing was completed before the product was released, and that the document is properly signed and dated. If anything seems incomplete, inconsistent, or unclear, contact the pharmacy for clarification.

If a provider cannot or will not produce a CoA, consider this a serious red flag. Legitimate compounding pharmacies - particularly 503B outsourcing facilities that are required to test every batch - maintain CoAs as part of their standard quality documentation and should have no hesitation in providing them to patients or prescribers upon request.

Red Flags for Unsafe Compounded Semaglutide Providers

The rapid growth of the compounded semaglutide market has attracted both legitimate pharmaceutical compounders and bad actors seeking to capitalize on consumer demand. Knowing what red flags to look for can protect you from products that range from ineffective to genuinely dangerous. The following warning signs should prompt serious caution or outright avoidance.

Red Flag 1: No Prescription Required

Semaglutide is a prescription medication in all forms - brand-name and compounded. Any provider that offers semaglutide without requiring a prescription from a licensed healthcare provider is operating outside the law. This includes websites that sell semaglutide directly to consumers without a medical evaluation, sources that label products as "research only" or "not for human consumption" to circumvent prescription requirements, and social media sellers or marketplace listings offering semaglutide without medical oversight.

A legitimate compounded semaglutide provider will always require either a prescription from your existing healthcare provider or a medical evaluation through an affiliated telehealth service with a licensed prescriber. There are no exceptions to this requirement.

Red Flag 2: Products Labeled "Research Only" or "Not for Human Use"

One of the most common strategies used by illegitimate sellers is to label semaglutide products as being for research purposes only. This labeling is designed to exploit a regulatory gray area where chemical suppliers can sell substances for legitimate laboratory research without meeting pharmaceutical manufacturing standards.

Products labeled for research use only have not been manufactured under cGMP conditions, have not been tested for sterility, potency, or endotoxin levels appropriate for human use, may contain impurities or contaminants that are acceptable for laboratory use but dangerous for injection, and provide no legal recourse if they cause harm. Under no circumstances should you inject a product labeled "for research use only" or "not for human consumption."

Red Flag 3: Overseas Sourcing or Shipping

Compounded semaglutide shipped from outside the United States presents multiple safety concerns. Foreign compounding operations are not subject to FDA oversight or state pharmacy board regulation. The product may not have been manufactured under any recognized quality standard. Cold chain integrity during international shipping is difficult to verify. The product may have passed through countries with lax pharmaceutical regulations. Customs seizure is possible, and importation of prescription drugs for personal use is generally prohibited.

Products sourced from overseas factories - particularly those in countries without strong pharmaceutical regulatory frameworks - carry the highest risk of contamination, incorrect potency, and substitution with different or adulterated substances. Some seized products marketed as semaglutide from overseas sources have been found to contain no semaglutide at all, or to contain different peptides or other substances entirely.

Red Flag 4: Inability or Refusal to Provide a Certificate of Analysis

As discussed in the previous section, a Certificate of Analysis is the document that proves a batch of compounded medication has been tested and meets quality specifications. Any provider that cannot produce a CoA when asked, claims CoAs are not applicable to their products, provides a CoA that is incomplete or does not match the product lot number, or becomes defensive or evasive when asked about testing should be avoided. There is no legitimate reason for a compounding pharmacy to be unable to provide a CoA for a product they have compounded and released.

Red Flag 5: Prices Significantly Below Market Rates

Compounded semaglutide involves real costs: pharmaceutical-grade active ingredient, sterile compounding labor, quality testing, cleanroom maintenance, cold chain shipping, and regulatory compliance. These costs establish a floor below which legitimate providers cannot operate without cutting corners on quality.

While compounded semaglutide is legitimately less expensive than brand-name products, prices that are dramatically below the prevailing market rate - particularly prices that seem too good to be true - often indicate that the provider is using lower-quality raw materials, skipping required quality testing, operating without proper cleanroom environments, not employing licensed pharmacists, or sourcing active ingredients from unverified or non-pharmaceutical-grade suppliers.

A reasonable price range for properly compounded semaglutide from a 503B facility, including medical evaluation and prescription, typically falls between $200 and $500 per month depending on the dose, supply duration, and provider model. Prices significantly below $150 per month for injectable semaglutide should prompt careful scrutiny of the provider's quality practices.

Red Flag 6: No Licensed Pharmacist Involvement

Compounding of prescription medications must be performed by or under the direct supervision of a licensed pharmacist. Any operation that compounds semaglutide without licensed pharmacist involvement is operating illegally. Warning signs include no pharmacist listed on the provider's website or materials, inability to provide the name and license number of the pharmacist-in-charge, no pharmacy license number available for verification, and customer service representatives who cannot connect you with a pharmacist for medication questions.

Red Flag 7: No Cold Chain Shipping

Semaglutide is a peptide that is sensitive to temperature. Compounded semaglutide injections should be shipped and stored under refrigerated conditions (36 to 46 degrees Fahrenheit or 2 to 8 degrees Celsius). Proper cold chain shipping requires insulated packaging, gel ice packs or other cooling media, and ideally a temperature indicator that confirms the product remained within the acceptable range during transit.

If you receive compounded semaglutide in a standard envelope, a non-insulated box, or packaging without any cooling elements, the product may have been exposed to temperatures that could degrade the active ingredient or compromise sterility. Products shipped without proper cold chain should be considered potentially compromised.

Red Flag 8: Marketing Claims of Equivalence to Brand Products

Compounded semaglutide is not FDA-approved and has not undergone the clinical trials required for FDA approval. Any provider that claims their compounded semaglutide is "the same as Ozempic" or "identical to Wegovy" or "FDA-approved" is making false and misleading claims. Legitimate providers will accurately describe their products as compounded semaglutide prepared by a licensed compounding pharmacy, not as equivalents to or substitutes for FDA-approved products.

Red Flag 9: Provider Discourages You from Consulting Your Own Doctor

A legitimate compounded semaglutide provider should encourage you to work with your own healthcare provider and should be transparent about what they are providing. Any provider that discourages you from discussing the medication with your doctor, suggests you do not need a doctor's involvement, or implies that their telehealth evaluation replaces your relationship with your primary care provider should be viewed with skepticism.

Red Flag 10: No Verifiable Physical Address or Pharmacy License

Every legitimate compounding pharmacy has a physical address and a verifiable pharmacy license in the state where it operates. Operations that use only PO boxes, have no verifiable physical location, cannot provide a pharmacy license number, or are not findable through their state board of pharmacy's license verification system may not be legitimate pharmacies at all.

The Semaglutide Salt Form Controversy

One of the most complex and consequential debates in the compounded semaglutide market centers on the question of salt forms. This issue sits at the intersection of pharmaceutical chemistry, federal drug regulation, and patient access, and it has significant implications for the legality and future of compounded semaglutide. Understanding the salt form controversy is essential for consumers who want to make informed decisions about their medication.

What Is a Salt Form and Why Does It Matter?

In pharmaceutical chemistry, many active drug ingredients exist in multiple forms. The base form is the active molecule itself. A salt form is created when the base molecule is combined with an acid or base to form a salt compound. Common examples include metformin hydrochloride (the hydrochloride salt of metformin), sertraline hydrochloride (Zoloft), and omeprazole sodium (the sodium salt of omeprazole).

Salt forms are widely used in pharmaceutical compounding and manufacturing because they can improve the stability, solubility, and handling characteristics of the active ingredient. In many cases, the salt form and the base form are considered therapeutically equivalent because the salt dissociates in the body to release the same active molecule.

The controversy surrounding semaglutide salt forms centers on whether semaglutide sodium and semaglutide acetate - salt forms commonly used by compounding pharmacies - are the "same" active ingredient as the base form of semaglutide used in FDA-approved products like Ozempic and Wegovy.

The FDA Position

The FDA has taken the position that semaglutide sodium and semaglutide acetate are different active ingredients from semaglutide base. Under this interpretation, compounding pharmacies cannot use the drug shortage exception to compound semaglutide sodium or semaglutide acetate as copies of FDA-approved semaglutide products, because they are not actually copies - they contain a different active ingredient.

The FDA's reasoning centers on the regulatory definition of an active ingredient and the agency's authority to determine whether different forms of a substance are the same or different for regulatory purposes. The FDA has noted that semaglutide sodium has a different molecular weight, different chemical properties, and has not been the subject of the clinical trials that supported the approval of semaglutide base in Ozempic and Wegovy.

From a practical enforcement standpoint, this position means that the FDA considers compounding pharmacies that use semaglutide sodium or semaglutide acetate to be producing products that contain unapproved new drugs, which cannot be legally marketed in the United States without an approved New Drug Application (NDA).

The Compounding Industry Position

Many compounding pharmacies, industry organizations, and some pharmacologists have challenged the FDA's position on salt forms. Their arguments generally include the following points.

Salt forms are standard pharmaceutical practice. The use of salt forms in compounding and manufacturing is a well-established, routine pharmaceutical practice. Many FDA-approved drugs are marketed as salt forms that are considered therapeutically equivalent to the base form. The FDA has historically treated salt forms and base forms as the same active ingredient for most regulatory purposes.

Therapeutic equivalence. Proponents argue that semaglutide sodium dissociates in aqueous solution (including body fluids) to release semaglutide base and sodium ions, making it therapeutically equivalent to semaglutide base for injection. The active molecule that interacts with GLP-1 receptors is the same regardless of whether it was formulated as the base or a salt form.

Compounding necessity. Some compounders argue that salt forms are necessary for the practical compounding of semaglutide, as the base form may have handling or stability characteristics that make it less suitable for certain compounding applications. Salt forms may offer improved solubility, stability, or ease of handling that help with accurate compounding.

Regulatory inconsistency. Critics point to what they see as inconsistency in the FDA's treatment of salt forms across different drugs, arguing that the agency's position on semaglutide salt forms is selectively applied rather than based on consistent scientific or regulatory principles.

Legal Challenges

The salt form question has been the subject of litigation in federal courts, with compounding pharmacies and industry groups challenging the FDA's position. These legal challenges have raised questions about the FDA's authority to determine what constitutes the "same" active ingredient for compounding purposes, whether the FDA's position on semaglutide salt forms is consistent with the agency's historical treatment of salt forms for other drugs, and whether the FDA's enforcement of its salt form position has followed proper administrative procedures.

The outcome of these legal challenges has significant implications for the future of compounded semaglutide access. If courts uphold the FDA's position, compounders using salt forms may be required to cease production. If courts reject the FDA's position, compounders may continue using salt forms under the drug shortage exception or other compounding authorities.

What This Means for Consumers

For consumers, the salt form controversy creates uncertainty, but it also provides another data point for evaluating providers. When considering a compounded semaglutide product, you should ask your provider whether the product contains semaglutide base, semaglutide sodium, semaglutide acetate, or another form. Understanding what form of semaglutide your product contains allows you to make an informed decision and to discuss the implications with your healthcare provider.

Providers that use semaglutide base - the same form used in FDA-approved products - avoid the regulatory uncertainty associated with salt forms entirely. This approach aligns with the FDA's stated position and provides the clearest regulatory footing. At FormBlends, we have chosen to work exclusively with 503B partners that use the base form of semaglutide for this reason.

Brand vs Compounded Semaglutide - Efficacy Comparison

One of the most common questions patients ask is whether compounded semaglutide works as well as brand-name Ozempic or Wegovy. This is a nuanced question that deserves a thorough, honest answer rather than a simple yes or no.

What the Science Tells Us

The clinical evidence supporting semaglutide for weight management and metabolic health comes from the STEP trial program (for weight management), the SUSTAIN trial program (for type 2 diabetes), the SELECT trial (for cardiovascular outcomes), and the FLOW trial (for chronic kidney disease). These trials used FDA-approved semaglutide manufactured by Novo Nordisk under validated, FDA-inspected manufacturing processes.

Compounded semaglutide products have not been through these clinical trials. No compounding pharmacy has conducted the type of large-scale, randomized, placebo-controlled trials that generated the clinical data supporting brand-name semaglutide. This is an important distinction that all consumers should understand.

However, this does not mean compounded semaglutide is inherently less effective. The active pharmaceutical ingredient - semaglutide - is the same molecule whether it comes from Novo Nordisk's manufacturing facility or from a 503B outsourcing facility. When compounded correctly using pharmaceutical-grade semaglutide base at the proper concentration and potency, the active ingredient that reaches your GLP-1 receptors is identical.

Where Differences May Exist

The potential differences between brand and compounded semaglutide are not in the active ingredient itself but in the supporting elements of the formulation and delivery system.

Excipients and formulation. Brand-name semaglutide products contain proprietary excipients (inactive ingredients) that have been optimized through extensive pharmaceutical development. These excipients influence the stability, absorption profile, and shelf life of the product. Compounded formulations may use different excipients, which could theoretically affect absorption characteristics, though the clinical significance of these differences for a subcutaneous injection is generally considered minimal.

Delivery device. Brand-name Ozempic and Wegovy use purpose-built autoinjector pens with precise dose selection mechanisms. Compounded semaglutide is typically supplied in multi-dose vials that require patients to draw up their dose using an insulin syringe. While both methods deliver the drug subcutaneously, the pen device provides more precise dose metering and may be easier for patients who are not comfortable with vials and syringes.

Potency consistency. Brand-name products undergo pharmaceutical manufacturing with validated processes designed to produce extremely consistent potency from vial to vial and batch to batch. Compounded products, while tested for potency, may have slightly more batch-to-batch variability within the 90 to 110 percent specification range. A product that tests at 92 percent of label claim on one batch and 108 percent on the next is within specification for both, but the patient experiences slightly different doses.

Stability and beyond-use dating. Brand-name semaglutide products have undergone extensive stability testing that supports expiration dates of 24 to 36 months. Compounded products typically have shorter beyond-use dates, often 30 to 90 days depending on the formulation and storage conditions. This difference is primarily one of convenience rather than safety, as long as the product is used within its BUD.

Clinical Experience

While no head-to-head clinical trials have compared brand and compounded semaglutide, the clinical experience of prescribers who have used both products provides relevant context. Many physicians, nurse practitioners, and physician assistants who prescribe compounded semaglutide from reputable 503B sources report that their patients experience similar appetite suppression, weight loss trajectories, gastrointestinal side effect profiles, and metabolic improvements as patients using brand-name products at equivalent doses.

This clinical experience, while not equivalent to randomized controlled trial data, is consistent with the pharmacological expectation that the same active ingredient delivered at the same dose via the same route should produce similar effects. The key qualifier is "at the same dose" - which is why potency testing and accurate compounding are so critically important.

The Honest Assessment

The most honest assessment of brand versus compounded semaglutide is this: brand-name products carry the strongest evidence base, the most rigorous manufacturing validation, and the full backing of FDA approval. They are the gold standard. Compounded semaglutide from FDA-registered 503B outsourcing facilities that use pharmaceutical-grade semaglutide base, perform comprehensive quality testing, and maintain cGMP compliance represents a quality alternative that is expected to produce comparable clinical effects based on pharmacological principles and clinical experience, though it lacks the specific clinical trial data of brand products.

The choice between brand and compounded semaglutide often comes down to access and affordability. For patients who have insurance coverage or can afford brand-name pricing, the FDA-approved product is the most straightforward choice. For the millions of patients who cannot access or afford brand-name semaglutide, properly compounded products from 503B facilities offer a reasonable alternative - provided the patient conducts due diligence on the provider's quality standards.

FormBlends Quality Standards and 503B Partners

At FormBlends, we believe that every patient deserves pharmaceutical-grade compounded medication, complete transparency about what they are receiving, and access to the documentation that proves their medication meets the highest quality standards. Our quality framework is built on the principles described throughout this guide - and we apply them without exception.

Our 503B Partnership Model

FormBlends exclusively partners with FDA-registered 503B outsourcing facilities for the compounding of injectable semaglutide and all other GLP-1 receptor agonist products. We made this decision because the 503B framework provides the highest level of safety assurance for injectable medications, and we believe that patient safety is not an area where cost optimization should drive decision-making.

Our 503B pharmacy partners meet the following requirements. They maintain current FDA registration as outsourcing facilities. They have demonstrated sustained compliance with cGMP requirements across multiple FDA inspections. They perform batch-level sterility testing, potency assay, endotoxin (LAL) testing, pH testing, and particulate matter testing on every lot of compounded semaglutide before release. They use the base form of semaglutide - the same active ingredient used in FDA-approved products - to avoid the regulatory uncertainty associated with salt forms. They maintain validated cold chain shipping processes to ensure product integrity from facility to patient. They provide Certificates of Analysis for every lot, available to patients and prescribers upon request.

Our Medical Oversight Model

FormBlends requires that every patient complete a comprehensive medical evaluation with a licensed healthcare provider before any compounded semaglutide is prescribed or dispensed. This evaluation includes a review of the patient's medical history, current medications, contraindications, and treatment goals. The prescribing provider determines whether semaglutide is appropriate and selects the starting dose and titration schedule.

We believe that the medical evaluation is not a checkbox to fulfill a regulatory requirement - it is a critical patient safety step that ensures the right medication reaches the right patient at the right dose. Our affiliated prescribers are trained in GLP-1 therapeutics and monitor patients throughout their treatment.

Transparency as a Core Value

We publish our quality standards openly because we believe that transparency is the best accountability mechanism in the compounded medication market. When you work with FormBlends, you can request the Certificate of Analysis for your specific lot at any time, verify the FDA registration status of our 503B pharmacy partners, review inspection reports for our partner facilities through the FDA public database, and contact our clinical team with questions about your medication.

We also encourage every patient to use the verification checklist in the next section of this guide to evaluate FormBlends and any other provider. If a provider cannot satisfy these basic quality checkpoints, they should not be compounding injectable medications.

Provider Verification Checklist - 10 Questions to Ask Any Compounding Pharmacy

Before starting compounded semaglutide from any provider, use checklist to evaluate their quality standards and regulatory compliance. These are the questions that separate legitimate, safety-focused providers from those that may be cutting corners. We encourage you to use this checklist to evaluate FormBlends and every other provider you consider.

Question 1: Is your compounding pharmacy registered with the FDA as a 503B outsourcing facility?

Why it matters: FDA registration as a 503B facility means the pharmacy has voluntarily submitted to federal oversight including cGMP compliance, regular inspections, adverse event reporting, and batch testing requirements. A "yes" answer that can be verified on the FDA Registered Outsourcing Facilities database is the single strongest indicator of quality and regulatory compliance.

What to do: Ask for the name and address of the compounding pharmacy. Search the FDA database at fda.gov to confirm registration. If the pharmacy is not listed, it is either a 503A pharmacy (state-regulated only) or it is not a registered compounding facility at all.

Question 2: Can you provide a Certificate of Analysis for the lot of semaglutide I will receive?

Why it matters: The CoA is your proof that the specific batch of medication has been tested and meets quality specifications. A provider that readily furnishes a CoA demonstrates both that testing is actually performed and that there is a culture of transparency around quality.

What to do: Request the CoA before or immediately after receiving your medication. Verify that the lot number matches your vial, that sterility testing shows "no growth" (not "pending"), that potency is within 90 to 110 percent of label claim, and that endotoxin testing was performed and passed.

Question 3: What form of semaglutide does your pharmacy compound with - base, sodium, or acetate?

Why it matters: The FDA has taken the position that semaglutide sodium and semaglutide acetate are different active ingredients from semaglutide base. Using the base form aligns with the FDA's position and avoids regulatory uncertainty. Providers using salt forms may face enforcement action that could disrupt your supply.

What to do: Ask specifically about the form of semaglutide used. If the provider cannot answer this question or does not know, that is itself a red flag.

Question 4: What quality testing is performed on every batch of compounded semaglutide?

Why it matters: Comprehensive batch testing is the technical foundation of compounded medication safety. At minimum, every batch of injectable semaglutide should be tested for sterility (USP 71), potency (HPLC assay), bacterial endotoxin (LAL per USP 85), pH, and particulate matter (USP 788).

What to do: Ask for a list of all tests performed on each batch. Compare the response to Table 3 in this guide. If any of the core tests are missing, ask why.

Question 5: Has the pharmacy received any FDA warning letters or state board enforcement actions?

Why it matters: Warning letters and enforcement actions indicate that a regulatory authority found significant compliance problems. While a resolved warning letter can indicate a commitment to corrective action, unresolved or repeated violations are serious concerns.

What to do: Ask the question directly and verify the answer by searching the FDA warning letters database and your state board of pharmacy disciplinary records. Do not rely solely on the provider's self-reporting.

Question 6: How is my medication shipped and what temperature controls are used?

Why it matters: Semaglutide is a temperature-sensitive peptide that should be shipped under refrigerated conditions. Exposure to heat can degrade the active ingredient and reduce potency. Proper cold chain shipping demonstrates attention to product integrity beyond the compounding facility.

What to do: Ask about insulated packaging, gel ice packs or other cooling media, and whether a temperature indicator is included in the shipment. If the provider ships in standard envelopes or non-insulated packaging, consider finding an alternative.

Question 7: Will I have a medical evaluation with a licensed healthcare provider before medication is prescribed?

Why it matters: Semaglutide is a prescription medication with contraindications, drug interactions, and potential side effects that require medical assessment. A provider that prescribes without a genuine medical evaluation is not operating in the patient's best interest and may not be operating legally.

What to do: Verify that the medical evaluation involves a licensed physician, nurse practitioner, or physician assistant who reviews your medical history, asks about current medications and conditions, and makes an individualized prescribing decision.

Question 8: Can you provide the name and license number of the pharmacist-in-charge?

Why it matters: Every compounding pharmacy must have a licensed pharmacist-in-charge who is responsible for the quality of compounded products. Being able to identify and verify this individual confirms that the pharmacy is operating under proper professional oversight.

What to do: Ask for the pharmacist's name, license number, and state of licensure. Verify the license through the appropriate state board of pharmacy website.

Question 9: What is the beyond-use date for the compounded semaglutide, and what stability data supports it?

Why it matters: The beyond-use date determines how long the compounded product can be used safely. BUDs should be based on actual stability testing data, not arbitrary assignment. A facility that has conducted stability studies can typically support longer BUDs, while facilities using default USP dates may assign shorter ones.

What to do: Ask about the BUD and what data supports it. A response that references stability testing or stability-indicating assay data is more reassuring than one that references only USP default dates.

Question 10: What happens if I experience an adverse event or have a quality concern about my medication?

Why it matters: A responsible provider should have clear processes for handling adverse event reports and quality complaints. 503B facilities are required to report serious adverse events to the FDA. Having a clear reporting pathway ensures that safety concerns are captured, investigated, and acted upon.

What to do: Ask about the adverse event reporting process. A provider that has a defined procedure, can explain how reports are handled, and can direct you to the FDA MedWatch system demonstrates a safety-first culture.

Scoring guidance: A provider with strong answers to 8 or more questions demonstrates excellent quality standards. A provider with 5 to 7 strong or acceptable answers may be adequate but warrants additional scrutiny. A provider with any red flag responses on questions 1, 2, 4, or 7 - the core safety questions - should be avoided regardless of other answers. Multiple red flags in any combination should disqualify the provider.

Real Enforcement Examples and Case Studies

Understanding how FDA enforcement works in practice - not just in theory - helps consumers appreciate why regulatory compliance matters. The following examples illustrate the types of enforcement actions that have occurred in the compounded semaglutide and related injectable compounding markets. These cases demonstrate that enforcement is real, consequences are significant, and patient safety is genuinely at stake.

Case Study 1: The NECC Tragedy - Why 503B Oversight Exists

The most important case study in compounding safety is the 2012 New England Compounding Center (NECC) incident, which directly led to the creation of the 503B outsourcing facility framework. NECC operated as a 503A pharmacy but was producing and distributing compounded steroid injections on a scale that was essentially pharmaceutical manufacturing without FDA oversight.

FDA investigation found that NECC's cleanroom environments were contaminated with mold and bacteria, the facility had inadequate environmental monitoring, products were released without complete sterility testing, and quality control procedures were insufficient for the scale of production. The contaminated methylprednisolone acetate injections caused a nationwide fungal meningitis outbreak resulting in 76 deaths and over 750 infections. Criminal convictions followed, including a second-degree murder conviction for the pharmacist-in-charge.

This tragedy was the catalyst for the Drug Quality and Security Act of 2013 and the creation of the 503B outsourcing facility category. Every 503B regulatory requirement - cGMP compliance, FDA inspection, batch testing, adverse event reporting - was designed to prevent a repeat of this catastrophe.

Case Study 2: Warning Letters for Salt Form Issues

The FDA has issued warning letters to compounding facilities that produced semaglutide products using salt forms that the agency considers to be different active ingredients from semaglutide base. In these cases, the FDA cited the facilities for producing copies of a commercially available drug using a substance that does not meet the requirements for compounding under the drug shortage exception.

These warning letters have required facilities to cease production of products using the cited salt forms, respond to the FDA with a corrective action plan, and demonstrate compliance with the FDA's position before resuming operations. Some facilities have complied by switching to semaglutide base, while others have challenged the FDA's position through legal channels.

Case Study 3: Insanitary Conditions Findings

FDA inspections of compounding facilities producing injectable products - including peptide products similar to semaglutide - have identified insanitary conditions at several facilities. Findings have included visible contamination in cleanroom environments, failure to maintain proper air pressure differentials between clean and non-clean areas, personnel entering cleanrooms without proper gowning procedures, equipment that was not properly cleaned or validated between uses, and environmental monitoring programs that were either absent or inadequate.

These findings are particularly alarming because they directly impact the sterility of injectable products. A cleanroom that fails to maintain proper environmental controls cannot reliably produce sterile injectable medications. Patients who received products from these facilities may have been exposed to contamination risks.

Case Study 4: Online Sellers Without Pharmacy Licensure

The FDA and state pharmacy boards have taken enforcement action against online sellers of what was marketed as semaglutide but was being sold without proper pharmacy licensure. In several cases, products were found to have been imported from overseas sources, were labeled as "research chemicals" or "peptides," lacked any quality testing documentation, and were sold without prescription requirements.

Testing of seized products from these sellers has revealed significant quality problems including products with no detectable semaglutide, products with incorrect concentrations, products contaminated with bacteria, and products containing unidentified substances that were not semaglutide. These cases illustrate the real dangers of purchasing injectable medications from unverified sources.

Case Study 5: Import Alerts and International Shipments

The FDA has placed import alerts on semaglutide products being shipped into the United States from foreign manufacturers that are not registered with the FDA and do not meet cGMP requirements. Import alerts authorize FDA field staff to detain products without physical examination when they arrive at US ports of entry.

Products detained under these import alerts have included bulk semaglutide powder intended for compounding, finished injectable semaglutide products, and products labeled as semaglutide that contained different substances. These enforcement actions highlight the risks of products sourced from outside the US pharmaceutical regulatory framework.

Patient Safety Incident Reports

The FDA's adverse event reporting system (FAERS) and MedWatch program collect reports of adverse events associated with pharmaceutical products, including compounded medications. While individual case reports cannot establish causation, patterns of reports can signal safety concerns that warrant investigation and consumer awareness.

Types of Adverse Events Reported with Compounded Injectables

Adverse event reports associated with compounded injectable products, including semaglutide and similar peptide products, have included the following categories of events.

Injection site reactions. Reports of redness, swelling, pain, and hardness at injection sites that were more severe than typically expected with properly compounded products. Some reports indicated injection site abscesses requiring medical treatment. While injection site reactions can occur with any injectable medication, unusually severe or frequent reactions from a specific product may indicate contamination or formulation problems.

Systemic infections. Reports of systemic bacterial infections that developed after injection of compounded products. These are among the most serious adverse events and can require hospitalization, intravenous antibiotics, and in severe cases, surgical intervention. Systemic infections following injection of a compounded product suggest a sterility failure in the compounding process.

Pyrogenic reactions. Reports of fever, chills, and rigors following injection, consistent with endotoxin exposure. Pyrogenic reactions indicate that the product may contain bacterial endotoxins, which should have been detected by LAL testing before the product was released.

Unexpected lack of efficacy. Reports from patients who experienced no therapeutic effect despite adherence to their prescribed regimen. While lack of efficacy can have multiple causes, it can indicate that the product contained less semaglutide than labeled (potency below specification) or that the active ingredient was degraded.

Unexpectedly severe side effects. Reports of gastrointestinal side effects or other semaglutide-related effects that were more severe than expected for the prescribed dose. This pattern could indicate that the product contained more semaglutide than labeled (potency above specification), delivering a higher dose than intended.

How Adverse Event Reporting Works

The FDA relies on voluntary reporting from patients, healthcare providers, and pharmacies to identify safety signals with compounded medications. This system has inherent limitations - underreporting is widely acknowledged, and many adverse events may never be reported to the FDA. For 503B outsourcing facilities, adverse event reporting is mandatory for serious events, which provides a more complete picture of safety than voluntary reporting alone.

Every patient using compounded semaglutide should know how to report an adverse event if one occurs. Reporting helps the FDA identify problematic facilities and products, supports enforcement actions that protect other patients, creates a documented record of your experience, and can trigger FDA investigation of the facility that produced your medication.

Protecting Yourself: What to Monitor

While using compounded semaglutide, you should monitor for and report the following to your healthcare provider and the FDA if they occur:

• Injection site reactions that are more severe than expected (large areas of redness, warmth, hardness, or pus)
• Fever or chills that develop within 24 hours of injection
• Signs of infection (fever, fatigue, body aches, chills) in the days following injection
• Side effects that seem disproportionate to your dose level
• Complete lack of any appetite suppression or therapeutic effect after several weeks of use
• Any change in the appearance of the medication (cloudiness, discoloration, particles)
• A vial that has a broken seal or shows signs of tampering
• Product that arrives warm or without proper cold chain packaging

If you experience a serious adverse event, seek medical attention immediately and then file a report with the FDA MedWatch program. Do not delay medical treatment to file a report - your health comes first. The reporting process is described in the next section.

Understanding cGMP Requirements: What Happens Inside a 503B Facility

Current Good Manufacturing Practice (cGMP) requirements represent the pharmaceutical industry's gold standard for ensuring drug product quality. When a 503B outsourcing facility commits to cGMP compliance, it submits to a comprehensive framework of regulations that governs every aspect of the compounding operation, from the raw materials that enter the facility to the finished products that leave it. Understanding what cGMP actually requires - in practical, operational terms - gives consumers a deeper appreciation for the quality assurance infrastructure that stands behind products from compliant 503B facilities.

Facility Design and Environmental Controls

A cGMP-compliant 503B facility is designed from the ground up to prevent contamination of compounded products. The physical layout must include defined clean zones with progressively higher air cleanliness levels as you move from general areas toward the actual compounding workspace. Air handling systems must maintain specific pressure differentials between zones, ensuring that clean air flows from the cleanest areas outward, preventing contaminated air from reaching the compounding area.

The primary engineering controls - the laminar airflow workbenches, biological safety cabinets, or compounding aseptic isolators where actual drug preparation takes place - must provide ISO Class 5 air quality. This classification means that each cubic meter of air contains fewer than 3,520 particles at 0.5 micrometers or larger. To put this in perspective, the ambient air in a typical office building can contain millions of particles of this size per cubic meter. Achieving and maintaining ISO Class 5 conditions requires HEPA-filtered air systems that are continuously monitored and regularly validated.

Temperature and humidity within the compounding areas must be controlled within defined ranges. Temperature affects both the comfort and behavior of compounding personnel (sweating can release skin particles and microorganisms) and the stability of pharmaceutical ingredients. Humidity control prevents condensation that could harbor microbial growth and affects the behavior of certain pharmaceutical ingredients during compounding.

The facility must also maintain cleaning and sanitization programs with validated procedures, defined frequencies, and documented effectiveness. Surfaces, equipment, floors, walls, and ceilings in cleanroom areas must be constructed of materials that are smooth, non-porous, and amenable to cleaning and sanitization. Regular environmental monitoring - including air sampling, surface sampling, and personnel monitoring - must demonstrate that the facility consistently meets its cleanliness specifications.

Personnel Training and Qualification

Under cGMP, personnel involved in sterile compounding must undergo comprehensive training that covers aseptic technique, gowning procedures, cleanroom behavior, and the specific compounding procedures they will perform. Training is not a one-time event - it requires initial qualification, regular reassessment, and documented competency verification.

Gowning procedures for cleanroom entry are precise and sequential. Personnel must don specific garments in a specific order in designated gowning areas. Typical cleanroom garments include shoe covers, head covers, face masks, sterile gloves (often double-gloved), and sterile gowns. The gowning process itself is trained and validated, with gowning qualification assessments performed to verify that personnel can gown without introducing contamination.

Media fill testing is a critical component of personnel qualification for sterile compounding. In a media fill test, the compounding technician performs the entire compounding procedure - from setting up materials to filling vials - using microbiological growth medium instead of the actual drug product. The filled units are then incubated and observed for microbial growth. Any growth indicates a failure in aseptic technique. Personnel must pass media fill testing before they are permitted to compound sterile products, and they must pass repeat testing at defined intervals (typically every six months to annually) to maintain their qualification.

Behavioral training covers cleanroom-specific behaviors that minimize particle generation and contamination risk. Rapid movements, talking, coughing, and even the way a person reaches for materials can generate particles that compromise air quality at the critical compounding zone. Personnel are trained to move slowly and deliberately, to keep conversations to a minimum, and to avoid actions that could direct air currents or particles toward open containers or critical surfaces.

Process Validation and Documentation

Every compounding process performed at a cGMP-compliant 503B facility must be validated. Process validation is the collection and evaluation of data that establishes scientific evidence that a process is capable of consistently delivering a quality product. For compounded semaglutide, this means demonstrating through documented studies that the compounding procedure reliably produces a product that meets all specifications for potency, sterility, pH, particulate matter, and other quality attributes.

Documentation under cGMP follows the principle that "if it was not documented, it did not happen." Every step of the compounding process is recorded in batch production records that capture the identity and quantity of every ingredient used, the identity of the personnel who performed each step, the equipment used, environmental conditions during compounding, any deviations from standard procedures, quality control test results, and the final disposition of the batch (released, rejected, or quarantined).

This documentation serves multiple purposes. It enables traceability - if a problem is identified with a product, the batch records allow investigators to trace every aspect of how that product was made. It enables quality trend analysis - by reviewing production and testing data over time, quality assurance personnel can identify trends that might indicate emerging problems before they result in out-of-specification products. And it provides accountability - every action taken during the compounding process is attributable to a specific person, creating a chain of responsibility.

Equipment Qualification and Maintenance

All equipment used in cGMP compounding must be qualified and maintained according to documented procedures. Qualification typically involves installation qualification (verifying that equipment is installed correctly), operational qualification (verifying that equipment operates correctly within defined parameters), and performance qualification (verifying that equipment consistently performs as intended during actual use).

Critical equipment for sterile compounding includes analytical instruments (such as HPLC systems used for potency testing), autoclaves (used for sterilization), cleanroom environmental monitoring equipment, balances (used for weighing ingredients), and primary engineering controls (laminar airflow workbenches, isolators). Each piece of equipment must have documented calibration schedules, preventive maintenance programs, and defined procedures for handling equipment failures or out-of-specification results.

Quality Control and Quality Assurance

Under cGMP, quality control and quality assurance are distinct functions that work together to ensure product quality. Quality control refers to the testing and inspection activities performed on materials and products - this includes the sterility testing, potency assays, endotoxin testing, and other analyses discussed earlier in this guide. Quality assurance is the broader system of procedures, processes, and organizational structures designed to prevent quality failures from occurring in the first place.

A strong quality assurance program at a 503B facility includes written standard operating procedures for every aspect of the operation, a change control system that requires formal evaluation and approval before any changes are made to materials, processes, or procedures, a deviation investigation process that requires root cause analysis and corrective action when anything does not go as planned, a complaint and adverse event handling process, a recall procedure for products that may need to be removed from the market, and regular management reviews of quality data and trends.

The quality unit at a 503B facility has the authority to approve or reject raw materials, in-process products, and finished products based on quality data. This authority is independent of production management, preventing production pressures from overriding quality decisions. The quality unit reviews and approves every batch record before a product is released for distribution, ensuring that all quality criteria have been met.

Raw Material Controls

The quality of the finished compounded product depends fundamentally on the quality of the raw materials used to make it. Under cGMP, incoming raw materials - including the active pharmaceutical ingredient (semaglutide), excipients, solvents, and packaging components - must be tested or verified against established specifications before they are used in compounding.

Active pharmaceutical ingredients used in 503B compounding should be sourced from suppliers that hold valid Drug Master Files (DMFs) with the FDA and can demonstrate that their manufacturing processes meet pharmaceutical quality standards. The 503B facility must evaluate and qualify its suppliers, test or verify incoming materials, and maintain documentation of material identity, purity, and quality.

For semaglutide specifically, the quality of the starting material is critical. Pharmaceutical-grade semaglutide is produced through complex peptide synthesis and purification processes that require specialized expertise and equipment. The purity, identity, and potency of the starting semaglutide must be verified before it is used in compounding. Certificates of Analysis from the raw material supplier should be reviewed and retained as part of the batch documentation.

Patient Guide to Storage and Handling of Compounded Semaglutide

Even the highest-quality compounded semaglutide can be compromised by improper storage and handling after it leaves the pharmacy. As the end user, you matters in maintaining the integrity of your medication from the moment you receive it until you administer the last dose. Following proper storage and handling practices ensures that every dose you inject is as safe and effective as the day it was compounded.

Receiving Your Shipment

When your compounded semaglutide arrives, inspect the shipment immediately. Check that the insulated packaging is intact and that the gel ice packs or cooling media are still cold (they do not need to be frozen, but they should still be noticeably cool). If a temperature indicator is included, check that it indicates the product remained within the acceptable temperature range during transit.

If the packaging appears damaged, the cooling media are completely warm, or the temperature indicator shows an out-of-range reading, contact your provider before using the medication. Do not assume the product is still good - temperature excursions can degrade the semaglutide peptide in ways that are not visible to the naked eye, potentially reducing potency or creating degradation products.

Remove the medication vial from the shipping packaging and place it in your refrigerator promptly. Do not leave it sitting on the counter or in the shipping box longer than necessary.

Refrigerator Storage

Store your compounded semaglutide vial in the main body of your refrigerator at a temperature between 36 and 46 degrees Fahrenheit (2 to 8 degrees Celsius). Avoid storing the vial in the refrigerator door, where temperatures fluctuate more due to frequent opening and closing. Also avoid placing the vial near the back wall of the refrigerator where it might freeze - freezing can damage the semaglutide peptide and alter the formulation.

Keep the vial in its original packaging or in a light-protected location within the refrigerator. While brief exposure to light during dose preparation is acceptable, prolonged light exposure can accelerate degradation of the peptide. If your vial does not come in an outer box, wrapping it in aluminum foil provides adequate light protection.

If you are using a multi-dose vial, note the date you first accessed it. Some compounded semaglutide products have a "once punctured" beyond-use date that is shorter than the unopened BUD. Follow the labeling instructions for how long the vial can be used after the first puncture.

Preparing and Administering Your Dose

Before drawing your dose, visually inspect the solution in the vial. It should be clear and colorless to slightly yellow. Do not use the product if it appears cloudy, contains visible particles, or has changed color. These changes may indicate contamination, degradation, or a formulation problem.

Use proper aseptic technique when accessing the vial. Clean the vial stopper with an alcohol swab before each access. Use a new, sterile syringe and needle for each injection. Draw up only the prescribed dose - do not attempt to adjust your dose without consulting your healthcare provider. Inject subcutaneously (under the skin) into the abdomen, thigh, or upper arm, rotating injection sites to minimize injection site reactions.

After injection, dispose of the used syringe and needle in a sharps container. Do not recap needles (to avoid needlestick injury), do not dispose of needles in regular trash, and follow your local regulations for sharps disposal.

What to Avoid

Do not freeze compounded semaglutide. Freezing can cause physical changes to the formulation and may damage the peptide. If your vial freezes accidentally, do not use it - contact your provider for a replacement.

Do not expose the vial to direct sunlight, high temperatures, or prolonged room temperature storage. If you need to transport your vial (for example, while traveling), use an insulated travel case with a gel ice pack. Do not place the vial directly against an ice pack - wrap the ice pack in a cloth or paper towel to prevent the vial from getting too cold.

Do not use the medication past its beyond-use date, even if the solution still looks clear and normal. The BUD represents the date through which the pharmacy has confirmed the product meets quality specifications. After the BUD, the potency and sterility of the product can no longer be assured.

Do not transfer the medication between vials, dilute it, or mix it with other substances unless specifically instructed to do so by your healthcare provider or pharmacist. Any manipulation of the product after it has been compounded introduces contamination risk and can affect potency and stability.

Understanding the Telehealth-to-Compounding Pipeline

Many consumers access compounded semaglutide through telehealth platforms rather than through traditional in-person medical visits and local pharmacies. Understanding how the telehealth-to-compounding pipeline works helps you identify where quality controls exist, where potential gaps may occur, and what questions to ask at each stage of the process.

How the Typical Telehealth Model Works

The typical process for obtaining compounded semaglutide through a telehealth platform follows a predictable flow. First, you complete an online health questionnaire that captures your medical history, current medications, allergies, body measurements, and treatment goals. Second, a licensed healthcare provider (physician, nurse practitioner, or physician assistant) reviews your questionnaire and may conduct a synchronous video visit or an asynchronous chart review, depending on state regulations and the platform's clinical model. Third, if the provider determines that semaglutide is appropriate, they write a prescription. Fourth, the prescription is transmitted to a compounding pharmacy that has a relationship with the telehealth platform. Fifth, the compounding pharmacy fills the prescription, and the medication is shipped directly to you.

This model offers genuine advantages for patients: convenience, accessibility (particularly for patients in rural areas or those with mobility limitations), often lower costs than brand-name alternatives, and faster access compared to scheduling an in-person appointment with a new provider and finding a local compounding pharmacy.

Where Quality Controls Should Exist

At each stage of this pipeline, quality controls should be in place to protect the patient.

Medical evaluation stage. The healthcare provider should conduct a genuine clinical assessment, not a rubber-stamp approval process. The evaluation should identify contraindications (such as personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2), potential drug interactions, conditions that might make semaglutide inappropriate or require dose adjustment, and patient-specific factors that influence the treatment plan. If every patient who fills out the questionnaire receives a prescription regardless of their answers, the medical evaluation is not functioning as a meaningful safety check.

Prescription stage. The prescriber should be licensed in the state where the patient resides, and the prescription should comply with state and federal prescribing requirements. For controlled telehealth prescribing, different states have different requirements regarding synchronous versus asynchronous consultations, prescriber-patient relationship establishment, and follow-up care obligations.

Compounding and dispensing stage. This is where the quality standards discussed throughout this guide apply. The compounding pharmacy should be a 503B outsourcing facility (or at minimum a licensed 503A pharmacy with strong voluntary quality practices), should perform the required quality testing on every batch, and should maintain proper documentation and labeling.

Shipping and delivery stage. Cold chain integrity must be maintained from the pharmacy to your doorstep. This includes insulated packaging, cooling media, and ideally temperature monitoring.

Ongoing care stage. The telehealth platform should provide mechanisms for ongoing clinical monitoring, dose adjustment based on response and tolerability, and reporting of adverse events. A platform that prescribes and ships medication but provides no follow-up care is not operating a complete clinical model.

Evaluating Telehealth Platforms

When evaluating telehealth platforms that offer compounded semaglutide, consider the following factors in addition to the pharmacy verification checklist discussed earlier in this guide.

Transparency about pharmacy partnerships. Does the platform identify which compounding pharmacy fills its prescriptions? Can you verify that pharmacy's registration, licensure, and inspection history? A platform that refuses to disclose its pharmacy partner is preventing you from conducting basic due diligence.

Clinical model quality. Does the medical evaluation feel thorough and personalized? Does the provider ask meaningful follow-up questions based on your health history? Are there clinical situations in which the platform has declined to prescribe (indicating genuine clinical judgment rather than automatic approval)?

Follow-up care availability. Can you contact a healthcare provider after your initial evaluation for questions, dose adjustments, or to report side effects? Is follow-up care included in the pricing or charged separately? How quickly do providers respond?

Customer service responsiveness. If you have a concern about your medication - appearance, temperature on arrival, adverse reaction - can you reach a knowledgeable person who can help? Is the customer service team trained to escalate clinical concerns to a healthcare provider or pharmacist?

Pricing transparency. Is the pricing clear and straightforward? Are there hidden fees for consultations, shipping, or follow-up visits? Does the pricing seem consistent with the costs of legitimate compounding (pharmaceutical-grade ingredients, quality testing, cold chain shipping, licensed clinical staff)?

The telehealth model is not inherently better or worse than the traditional in-person model for accessing compounded semaglutide. Both models can deliver safe, quality medication when operated by legitimate companies with genuine clinical oversight and quality-focused pharmacy partnerships. The key is to apply the same standards of verification regardless of how you access the medication.

How to Report Concerns About Compounded Medications

If you experience a problem with a compounded semaglutide product - whether an adverse health event, a quality concern, or a suspicion about a provider's legitimacy - you have several reporting pathways available. Reporting is important not just for your own situation but for the protection of other patients who may be using the same product or provider.

FDA MedWatch: Reporting Adverse Events and Quality Problems

The FDA MedWatch program is the primary federal system for reporting adverse events and quality problems with pharmaceutical products, including compounded medications. You can submit a report through the following channels.

Online: Submit a report through the FDA MedWatch online reporting form at fda.gov/medwatch. The online form allows you to provide detailed information about the product, the adverse event, and your medical history.

By phone: Call 1-800-FDA-1088 (1-800-332-1088) to report an adverse event or request a paper reporting form. Phone reporting is available during business hours and may be helpful if you prefer to speak with someone directly.

By mail or fax: Download the MedWatch 3500 form from the FDA website, complete it, and submit by mail or fax. The mailing address and fax number are printed on the form.

What Information to Include in Your Report

When filing a MedWatch report, include as much of the following information as possible to help the FDA investigate your concern.

About the product: the product name (compounded semaglutide), the compounding pharmacy name and address, the lot number from your vial, the concentration and volume, the beyond-use date, and any information from the Certificate of Analysis. About the event: a detailed description of what happened, when it started in relation to your last injection, the severity of the event, any medical treatment you received, the outcome, and whether you continued or discontinued the medication. About you: your age, sex, weight, other medical conditions, and other medications you are taking (to help the FDA assess potential contributing factors).

Preserve the product if possible. Do not discard the remaining medication, the vial, or the packaging. These may be needed for testing if the FDA investigates your report. Store the vial under refrigeration and keep all packaging and labeling materials.

State Board of Pharmacy Complaints

In addition to FDA reporting, you can file a complaint with the state board of pharmacy in the state where the compounding pharmacy is located. State boards of pharmacy have jurisdiction over pharmacy licensure and can investigate complaints related to compounding practices, pharmacist conduct, and pharmacy operations.

Each state board of pharmacy has its own complaint process, typically available through the board's website. When filing a state complaint, include the pharmacy name, address, and license number (if known), and describe the nature of your concern.

Your Healthcare Provider

If you experience an adverse event, contact your healthcare provider as your first step. Your provider can assess whether the event is related to the compounded medication, provide appropriate medical treatment, document the event in your medical record, and file a MedWatch report on your behalf (healthcare provider reports often receive higher priority in FDA review).

Consumer Protection Agencies

If you believe a compounded semaglutide provider is engaged in fraudulent or deceptive business practices, you can also file complaints with the Federal Trade Commission (FTC) through ftc.gov/complaint, your state attorney general's consumer protection division, and the Better Business Bureau. These agencies address business practices rather than medication quality specifically, but they provide additional accountability mechanisms for providers that may be misleading consumers.

Frequently Asked Questions About Compounded Semaglutide Safety

The following frequently asked questions address the most common concerns patients have about the safety and quality of compounded semaglutide. Each answer draws on the detailed information covered throughout this guide.

Making an Informed Decision About Compounded Semaglutide Safety

The compounded semaglutide market exists because millions of Americans need access to effective weight management and metabolic health medications that are often priced beyond their reach or unavailable due to supply constraints. This is a legitimate medical need, and compounding pharmacies matters in filling it. But not all compounded products are equal, and the safety of what you inject into your body depends on choices you can make as an informed consumer.

The core principles of this guide can be distilled into a simple framework for decision-making. First, prioritize 503B outsourcing facilities over 503A pharmacies for injectable medications. The mandatory FDA oversight, cGMP compliance, and batch-level testing provide the strongest safety assurance available in the compounded medication market. Second, always request and review the Certificate of Analysis for your specific lot. The CoA is your proof that the medication has been tested and meets quality specifications. Third, verify before you trust. Check FDA registration, search for warning letters, confirm pharmacy licensure, and ask the ten questions in the verification checklist. Fourth, recognize red flags immediately. No prescription requirement, overseas sourcing, research-only labeling, and inability to provide a CoA are disqualifying concerns that should end your consideration of a provider. Fifth, report problems. If you experience an adverse event or identify a quality concern, report it to the FDA and your state board of pharmacy. Your report protects other patients.

At FormBlends, we built our quality framework around these principles because we believe that patient safety is the foundation of everything we do. We chose 503B outsourcing facility partners, insisted on semaglutide base rather than salt forms, required comprehensive medical evaluations, and committed to full transparency because these are the standards that injectable compounded medications demand.

Compounded semaglutide can be a safe, effective, and more accessible alternative to brand-name GLP-1 medications - when it comes from the right source. We hope this guide gives you the knowledge and tools to verify that your source meets the standard you deserve.

Medical Disclaimer

This article is for educational and informational purposes only and does not constitute medical advice. The information provided is not intended to diagnose, treat, cure, or prevent any disease or condition. Always consult with a qualified healthcare provider before starting, stopping, or changing any medication, including compounded semaglutide.

Compounded medications are not FDA-approved. While the active ingredients used in compounding may be the same as those in FDA-approved products, compounded preparations have not undergone the same clinical trials, manufacturing validation, or FDA review process. The information in this guide about 503A and 503B regulations, quality testing, and enforcement actions is based on publicly available regulatory information and may not reflect the most current regulatory developments.

FormBlends does not compound medications directly. Compounding is performed by independently licensed, FDA-registered 503B outsourcing facility partners. FormBlends helps with access to compounded medications through affiliated healthcare providers and pharmacy partnerships.

Sources and References

• FDA. Drug Quality and Security Act (DQSA), Public Law 113-54. 2013.
• FDA. Registered Outsourcing Facilities database. fda.gov.
• FDA. Warning Letters related to compounding. fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters.
• United States Pharmacopeia. USP General Chapter 797: Pharmaceutical Compounding - Sterile Preparations. Revised 2023.
• United States Pharmacopeia. USP General Chapter 71: Sterility Tests.
• United States Pharmacopeia. USP General Chapter 85: Bacterial Endotoxins Test.
• United States Pharmacopeia. USP General Chapter 788: Particulate Matter in Injections.
• FDA. Current Good Manufacturing Practice (cGMP) Regulations. 21 CFR Parts 210 and 211.
• FDA. MedWatch: The FDA Safety Information and Adverse Event Reporting Program. fda.gov/safety/medwatch.
• FDA. Compounding and the FDA: Questions and Answers. fda.gov.
• National Association of Boards of Pharmacy (NABP). State compounding regulations and inspection standards.
• Novo Nordisk. Ozempic (semaglutide) prescribing information. 2024.
• Novo Nordisk. Wegovy (semaglutide) prescribing information. 2024.